Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.48 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.47 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10613175 | 1.00 | CYP19A1 (0.48) | CYP19A1CYP17A1SLC22A2SLC47A1MAPT | |
| Hydrochloric Acid SCHEMBL10613170 | 0.98 | MAPT (0.48) | CYP19A1CYP17A1SLC22A2SLC47A1MAPT | |
| SCHEMBL9608681 | 0.84 | CYP19A1 (0.50) | CYP19A1CYP17A1MAPTALDH1A1EPHX1 | |
| SCHEMBL27437399 | 0.84 | CYP19A1 (0.50) | CYP19A1CYP17A1MAPTALDH1A1EPHX1 | |
| SCHEMBL14673993 | 0.84 | CYP17A1 (0.50) | CYP19A1CYP17A1MAPTALDH1A1EPHX1 | |
| SCHEMBL23417222 | 0.83 | DPP4 (0.40) | CYP19A1CYP17A1SLC22A2SLC47A1ALDH1A1 | |
| SCHEMBL20078523 | 0.81 | CYP19A1 (0.48) | CYP19A1CYP17A1MAPTALDH1A1EPHX1 | |
| SCHEMBL4742227 | 0.81 | CYP19A1 (0.48) | CYP19A1CYP17A1MAPTALDH1A1EPHX1 | |
| SCHEMBL958155 | 0.81 | CYP19A1 (0.48) | CYP19A1CYP17A1MAPTALDH1A1EPHX1 | |
| SCHEMBL3217474 | 0.81 | CYP17A1 (0.48) | CYP19A1CYP17A1MAPTALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332246-A1 | ENHANCED EXPRESSION VIA AUTOTRANSPORTERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250026818-A1 | MALE CONTRACEPTION | Sciencemed Spóka z ograniczon odpowiedzialnoci (PL) | 2025-01-23 | — | — | US | disclosed |
| US-20240309390-A1 | MINICELLS FROM HIGHLY GENOME REDUCED ESCHERICHIA COLI: CYTOPLASMIC AND SURFACE EXPRESSION OF RECOMBINANT PROTEINS AND INCORPORATION IN THE MINICELLS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4419122-A1 | MALE CONTRACEPTION | SCIENCEMED SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2024-08-28 | — | — | EP | disclosed |
| US-20240261394-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES AGAINST CLASS I FUSION PROTEIN VIRUSES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-08-08 | — | — | US | disclosed |
| US-11819542-B2 | Immunotherapeutic method for treating lung cancer by administering a polypeptide comprising an epitope of hZP3 | PANTARHEI BIOSCIENCE B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| WO-2023081861-A1 | ENHANCED EXPRESSION VIA AUTOTRANSPORTERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023066923-A1 | MALE CONTRACEPTION | RAHMAN NAFIS (FI) | 2023-04-27 | — | — | WO | disclosed |
| EP-4138901-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES AGAINST CLASS I FUSION PROTEIN VIRUSES | University of Virginia Patent Foundation (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20230027709-A1 | COMPOSITIONS AND METHODS FOR REGULATING SAS1R | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-01-26 | — | — | US | disclosed |
| CN-1200727-C | Pharmaceutical compositions based on alpha-cyclodextrins for the oral administration of LH-RH analogues | THERAMEX (MC) | 2005-05-11 | — | — | CN | disclosed |
| WO-2004019881-A9 | HYPOCRETIN ADMINISTRATION AS A TREATMENT FOR OBESITY | UNIV CALIFORNIA (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004019881-A2 | HYPOCRETIN ADMINISTRATION AS A TREATMENT FOR OBESITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1322328-A2 | VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS | Children's Hospital & Research Center at Oakland (US) | 2003-07-02 | — | — | EP | disclosed |
| CN-1355810-A | Prodrugs of thrombin inhibitors | BASF AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| WO-2002009643-A2 | VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2002-02-07 | — | — | WO | disclosed |
| CN-1324241-A | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues | THERAMEX (MC) | 2001-11-28 | — | — | CN | disclosed |
| CN-1289341-A | Thrombin inhibitors | BASF AG (DE) | 2001-03-28 | — | — | CN | disclosed |
| EP-0675902-A1 | ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-10-11 | — | — | EP | disclosed |
| WO-1994014843-A1 | ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027709-A1 | COMPOSITIONS AND METHODS FOR REGULATING SAS1R | NASP, MSL1, ZP1 | CYP19A1 878/4885CYP17A1 1718/4885SLC22A2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.